Drug Abuse: Origins and Interventions
For individuals in the U.S. & U.S. territories
Why are some people more likely than others to become addicted to drugs? What are the best ways to prevent and treat addiction? How should we shape our public policies about drug addiction? Scientific perspectives on drug abuse are changing, and Drug Abuse: Origins and Interventions provides the reader a comprehensive introduction to current ideas and research about the causes of drug abuse and its prevention and treatment. It also crystallizes the effects that research and public attitudes can and do have on our national drug abuse policies. The new discoveries and fresh theoretical perspectives presented here will benefit clinician and scientist alike, as well as anyone who cares about the societal effects of drug abuse.
List of Contributors
—Alan I. Leshner
- The Etiology of Drub Abuse: Mapping the Paths
—Meyer D. Glantz, Naimah Z. Weinberg, Lucinda L. Miner, and James D. Colliwer
- Frontline Surveillance: The Community Epidemiology Work Group on Drug Abuse
—Zili Sloboda and Nichokzs 1. Kozel
- The Impact of Public Attitudes on Drug Abuse Research in the Twentieth Century
—Dawid F. Musto
- Explaining Attitudes About Public Policy on Drug Availability: The Role of Expectancies About Drinking and Drug Effects
—Robin Room and Angela Paglia
- A Developmental Psychopathology Perspective on Drug Abuse
- Why People Use, Abuse, and Become Dependent on Drugs: Progress Toward a Heuristic Model
—Robert J. Pandina and Valerie L. Johnson
- Prevention and Treatment of Drug Abuse: Use of Animals Models to Find Solutions
—Marilyn E. Carroll
- Neurobiology of Drug Addiction
—George F. Koob, S. Barak Caine, Petri Hyytia, Athina Markou, Loren H. Parsons, Amanda J. Roberts, Gery Schulteis, and Friedbert Weiss
- Ethnic Minority Women, Health Behaviors, and Drug Abuse: A Continuum of Psychosocial Risks
- The Prevention of Drug Abuse: Interrupting the Paths
- The Treatment of Drug Abuse: Changing the Paths
—Christine R. Hartel and Meyer D. Glantz
- Adolescent Drug Abuse Prevention: Current Findings and Future Directions
—Gilbert J. Botwin
- HIV Prevention: We Don't Need to Wait for a Vaccine
—Thomas J. Coates and Chris Collins
- An Ecodevelopmental Framework for Organizing the Influences on Drug Abuse: A Developmental Model of Risk and Protection
—José Szapocmik and J. Douglas Coatsworth
- Development, Evaluation, and Dissemination of Effective Psychosocial Treatments: Levels of Disorder, Stages of Care, and Stages of Treatment Research
—Marsha M. Linehan
- Therapeutic Communities: Research and Applications
—George De Leon
- Scientific Basis for Tobacco Policy: Nicotine Research Travails
—Jack E. Henningfield and Christine R. Hartel
About the Editors
Meyer D. Glantz, PhD, is the associate director for science and acting deputy director of the Division of Epidemiology and Prevention Research of the National Institute on Drug Abuse (NIDA), National Institutes of Health. At NIDA, Dr. Glantz has previously served as the chief of the Epidemiology Research Branch and the director of the Etiology Research Program. Prior to coming to NIDA he worked as a researcher and clinician at the Veterans Administration Clinic in Boston.
Dr. Glantz is a Fellow of the American Psychological Association and serves as a consultant to and board member of a variety of scientific and professional organizations and publications. He is the author of numerous articles and chapters on substance abuse, drug abuse etiology, cognitive therapy, and the elderly and has edited several volumes including Vulnerability to Drug Abuse, Biobehavioral Research Approaches to Drug Abuse Etiology, and Resilience and Development: Positive Life Adaptations. In addition, he maintains a private clinical practice in the Washington, DC area, supervises other clinicians, and is a lecturer for the Montgomery County Adult Education program. Dr. Glantz received his doctorate from Harvard University in 1979.
Christine R. Hartel, PhD, is associate executive director for science at the American Psychological Association, where she represents the scientific and science policy interests of the association to federal and state agencies, other scientific and professional organizations, and APA governance groups. She was elected a Fellow of the Association this year. Dr. Hartel worked for six years at the National Institute on Drug Abuse, awarding grants and contracts for basic and clinical research on drug abuse in the fields of neuroscience, behavior, pharmacology, and chemistry. She has written many articles, technical reports, and book chapters on drugs and the brain, amphetamine research, and the medical uses of marijuana. She also edited the book Biomedical Approaches to Illicit Drug Demand Reduction.
Dr. Hartel has been a consultant to the World Health Organization on the effects of marijuana. As a research psychologist at the U.S. Army Research Institute for the Behavioral and Social Sciences, she studied the cognitive effects of drugs and other stressors on soldier performance, as well as their implications for the design of weapons systems. In 1985, Dr. Hartel received the Army's Research and Development Award, the highest civilian honor conferred by the Army for technical excellence. Dr. Hartel received her PhD in biopsychology from the University of Chicago in 1985.